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ABSTRACT
Alport syndrome (AS) is a genetic disease characterized by
haematuric glomerulopathy variably associated with hearing
loss and anterior lenticonus. It is caused by mutations in the
COL4A3, COL4A4 or COL4A5 genes encoding the
a3a4a5(IV) collagen heterotrimer. AS is rare, but it accounts
for >1% of patients receiving renal replacement therapy.
Angiotensin-converting enzyme inhibition slows, but does not
stop, the progression to renal failure; therefore, there is an
urgent requirement to expand and intensify research towards
discovering new therapeutic targets and new therapies. The
2015 International Workshop on Alport Syndrome targeted
unmet needs in basic science, genetics and diagnosis, clinical
research and current clinical care. In three intensive days,
more than 100 international experts including physicians,
geneticists, researchers from academia and industry, and
patient representatives from all over the world participated in
panel discussions and breakout groups. This report summa-
rizes the most important priority areas including (i) under-
standing the crucial role of podocyte protection and regenera-
tion, (ii) targeting mutations by new molecular techniques for
new animal models and potential gene therapy, (iii) creating
optimal interaction between nephrologists and geneticists for
early diagnosis, (iv) establishing standards for mutation
screening and databases, (v) improving widespread accessibil-
ity to current standards of clinical care, (vi) improving collabo-
ration with the pharmaceutical/biotech industry to investigate
new therapies, (vii) research in hearing loss as a huge unmet
need in Alport patients and (viii) the need to evaluate the risk
and beneﬁt of novel (including ‘repurposing’) therapies on an
international basis.
Keywords: Alport syndrome, chronic kidney disease, guide-
lines, hereditary kidney disease, nephroprotection
INTRODUCTION
The 2015 International Workshop on Alport Syndrome (AS)
was held at the Old Gauss Observatory in Go¨ttingen, Germany
from 25 to 27 September. As a continuation of the successful
concept of the previous workshop in January 2014 [1], this
meeting covered clinical, genetic and basic science aspects of
AS. More than 100 clinicians, researchers, patient organizations
and pharmaceutical/biotech industry representatives from all
over the world intensively discussed various topics. The overall
goal of the meeting was focussed on strengthening worldwide
research strategies and collaborations and on developing and
evaluating new and existing treatments.
KEYNOTE PRESENTATIONS FROM
PARALLEL RESEARCH AREAS
Charles Streuli, a cell and matrix biologist from Manchester,
UK, presented new concepts relating to the regulation of extrac-
ellular matrix (ECM) and how this can influence cell fate. These
included the mechanical properties of tissue and how ageing- or
disease-associated changes in tissue stiffness can predispose to
cancer. The concept that tissue stiffness can influence cell fate is
not new, and indeed it is known that stem cells differentiate to
different lineages (adipose or bone) depending on ECM stiffness
[2]. However, the association between tissue stiffness and the
development of cancer is more recent [3]. Streuli also intro-
duced the concept of the body clock and the regulation of the
ECM. There is growing evidence that circadian rhythms influ-
ence a range of physiological processes and the ECM is no
exception [4]. The relevance of these observations for patient
management may be through the timing of drug therapies, as
recently demonstrated in a model of inflammatory lung disease
[5].
Alexander Nystrom, a group leader at the Klinik fu¨r
Dermatologie und Venerologie, Freiburg, Germany, talked
about the skin disorder dystrophic epidermolysis bullosa
(DEB). As with AS, this devastating skin disease is caused by
genetic mutations in a collagen gene, COL7A1 [6]. Collagen VII
is important for tight attachment of the dermis to the epidermal
basement membrane, and loss of function results in a blistering
skin disorder with increased propensity for tissue scarring.
Proposed treatment options for patients with DEB have
included bone marrow transplantation, collagen VII protein
replacement therapy, gene therapy, fibroblast therapy and
induced exon-skipping therapy [7]. A number of these
approaches have also been considered for AS. Nystrom further
described the creation of a mouse model of DEB, and in this
model, transforming growth factor (TGF)-beta was up-
regulated in wounds. Treatment with the angiotensin II recep-
tor inhibitor (ARB) losartan was associated with reduced scar-
ring, suggesting an anti-fibrotic role for this therapeutic agent.
In keeping with a role for tissue mechano-biology, this study
also reported a softer dermis after extended losartan treatment
[8].This example of repurposing the use of existing therapies
allows for accelerated clinical impact.
The AS is characterized by abnormal ECM accumulation in
the form of glomerulosclerosis and ultimately tubulointerstitial
fibrosis. Michael Zeisberg, a group leader and clinician scientist
from Go¨ttingen, Germany, gave a keynote talk on the role of
epigenetics in renal fibrosis. He described the role of Rasal1 as
an epigenetic modifier that inhibits the Ras-GTP oncoprotein
[9]. This study found hyper-methylation of RASAL1 by the
methyltransferase Dnmt1 and that gene reduction of Dnmt1 in
a mouse model was associated with reduced renal fibrosis.
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|Zeisberg’s team have gone on to demonstrate that free DNA
fragments of the promoter region of RASAL1 can be detected in
peripheral blood and that these levels correlate with RASAL1
levels in kidney tissue and in turn with the extent of fibrosis
[10]. In the same study, the authors found that RASAL1 DNA
levels were reduced following treatment with low dosage of the
anti-hypertensive drug dihydralazine. Therefore, this candidate
represents a potential new biomarker for renal fibrosis and per-
haps even a new therapeutic target.
Providing great insight into the bench to bedside pathway
for gene therapy Stephen Hyde, Head of the Oxford University
Gene Medicine Research Group, gave another keynote presen-
tation. After the discovery of the first gene defect in cystic fibro-
sis (CF) in 1988, Hyde described the race to develop a cure with
gene therapy. This started with the generation of a mouse model
in which it was established that gene transfer would be possible
[11]. There were then numerous combinations of genetic con-
structs coupled with a delivery system to establish the most effi-
cient transfer combination. Ultimately, these efforts resulted in
the development of the CF consortium in the UK where
research teams from three leading institutions (Edinburgh
University, Imperial College London and University of Oxford)
combined efforts to launch the first clinical trial. This Phase II
trial was recently reported and demonstrated a modest
improvement in lung function in CF patients [12]. The trial
recruited an unselected cohort of patients and in addition, dur-
ing the trial development, a new small-molecule therapy
became available to a small subgroup of CF patients. Hyde dis-
cussed the importance of patient selection and indicated that
further improvement in gene therapy would be possible with
the use of viral vectors for gene delivery.
Small-molecule therapy options are also being considered
for AS, and a Phase II clinical trial of the anti-fibrotic agent tar-
geting microRNA-21 (miR-21) is currently underway. Markus
Bitzer, a nephrologist and group leader at the University of
Michigan, USA, provided further insight into the actions of
miR-21. An uncontrolled RNA-sequencing study in PIMA
Indians (who are especially prone to developing diabetic nephr-
opathy) found some correlation in that glomerular miR-21 was
very abundant [13]. miR-21 was also increased in a mouse
model of diabetic kidney disease, and loss of miR-21 in these
mice accelerated the progression of kidney disease [13]. The
authors proposed that miR-21 is an important regulator of
TGF-beta, itself a major player in fibrogenesis. Bitzer also
described the NEPTUNE consortium, established for the study
of nephrotic syndrome, and highlighted the importance of links
with the pharmaceutical/biotech industry for the progression of
research in this area.
The wider therapeutic targets for AS were considered by
Hans Joachim Anders, nephrologist and group leader from
Munich, Germany. He reminded us of the need to consider the
number of nephrons a patient has from birth as this may ulti-
mately impact upon the severity of genetic or acquired renal dis-
ease. Birth weight is a strong predictor of nephron number [14],
and whilst regeneration possibly exists, Anders explained that
this is likely to represent a very small component of renal
growth with a much greater contribution from nephron hyper-
trophy. With regard to therapies for AS, Anders described the
potential for multi-drug usage. A recent meta-analysis of com-
bination therapy to lower blood pressure in diabetic kidney dis-
ease demonstrated once again that angiotensin-converting
enzyme (ACE) inhibitors and ARBs were the most effective
agents at prolonging renal survival but that combination ther-
apy needed to be balanced against the risks of hyperkalaemia
and acute kidney injury [15]. The effect of the mineralocorticoid
antagonist finerenone was also discussed, and a recent clinical
trial in diabetic kidney disease found reduced albuminuria in
patients treated with a combination of ACE inhibitors or ARBs
and finerenone [1]. These clinical trial findings may be relevant
for strategies to treat AS to delay the progression of renal
disease.
UNMET NEEDS IN RESEARCH: REPORT OF
THE BASIC SCIENCE BREAKOUT GROUP
The workshop also provided the opportunity for small group
discussions, followed by panel discussion, with feedback from
the whole audience. In the basic science group, a number of
unmet needs were identified. The need to establish an
‘International Alport Syndrome Research Alliance’ to provide
legitimacy to our individual efforts was raised. In addition, the
need for an international biobank was discussed and envisaged
to be in collaboration with patients and clinicians, and to pro-
vide material (blood, urine and tissue samples) for state-of-the-
art analyses of disease progression, as well as material to validate
findings from mouse models. Possibilities for maintaining
research tools, including human cell lines, antibodies, plasmids,
mouse colonies, etc., were discussed with the final goal of facili-
tating sharing among members of the AS research community.
The accessibility of the biobank by pharmaceutical/biotech
industry would need to be sensitively explained to patients. The
need to harness the power and knowledge of developmental
and stem cell biology and regenerative medicine to improve
research tools and to aid discovery was highlighted. The partici-
pants also agreed that it is important to increase our knowledge
about human kidney development in order to understand
podocyte specification and glomerular basement membrane
(GBM) deposition. In terms of new therapies, a focus on meth-
ods to strengthen or supplement the existing collagen IV a1, 1
and 2 network to slow the decline in kidney function was con-
sidered. In addition, the feasibility of expressing a3/4/5 in endo-
thelial cells by viral transduction was raised, as was
consideration of molecular techniques to correct glycine substi-
tutions and nonsense mutations (such as induced stop codon
skipping). Given the presumed central role of podocytes, a focus
on assessing whether foot process effacement and loss of podo-
cytes could be halted through inhibition of pro-fibrotic, pro-
apoptotic or aberrant collagen-induced signalling was raised, as
was the question of whether protein folding and/or endoplas-
mic reticulum stress could be ameliorated with chemical chap-
erones or other small molecules.
The group acknowledged the need for the pharmaceutical/
biotech industry’s expertise to help direct research efforts
towards achievable therapeutic strategies. The ultimate need for
precision medicine was also discussed and in particular the
918 O. Gross et al.
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|need to identify modifier genes and use their activities as poten-
tial therapeutic targets. The advent of next-generation sequenc-
ing technology now offers the possibility of translating this goal
into reality, but large cohorts of patients stratified on the basis
of detailed molecular and clinical characterizations are needed.
As demonstrated by the Italian group, genes of the ECM or
podocyte cytoskeleton represent modifier candidates that can
be investigated by exome/genome panels before an unbiased
data analysis.
Finally, the need to attract researchers into under-
represented areas of research in AS was raised, and the example
of research in hearing impairment was high on this agenda.
UNMET NEEDS IN DIAGNOSIS : REPORT OF
THE GENETICS & DIAGNOSIS BREAKOUT
GROUP
The Genetics & Diagnosis breakout group sessions (and a spe-
cial pre-meeting) discussed late-breaking achievements and
developments in the fast-growing field of molecular genetics
extensively in the context of earlier and more accurate diagno-
sis. Why is this issue so important? It is highly likely that the
current EARLY PRO-TECT Alport trial of early ACE inhibition
(www.clinicaltrials.gov; identifier NCT01485978) with ramipril
[16] will be followed by other trials as candidate therapies
emerge from basic science research or from other clinical trials
[17]. It is thus essential that all patients who enrol in these trials
have their diagnosis confirmed at the DNA level so that any
possible genetic factors that may influence response to therapy
are identified. The group discussion covered the most recent
reviews and expert recommendations about five different
topics.
Achieving an early diagnosis: the role of geneticists and
nephrologists
There is considerable evidence that early diagnosis and treat-
ment, if indicated, improve the long-term prognosis in AS [18,
19], and this evidence forms the basis for treatment recommen-
dations [20, 21]. In order to achieve earlier diagnosis, there
needs to be greater awareness of the possibility of a diagnosis of
AS in any patient presenting with persistent haematuria. In
childhood, this is more likely to be achieved if any child with
unexplained, persistent haematuria is referred to a paediatric
nephrologist. Genetic testing is generally replacing more inva-
sive investigations such as kidney biopsy and skin biopsy and is
likely to achieve confirmation of the diagnosis at a molecular
level in around 95% of patients who have AS [21]. In some fam-
ilies where the diagnosis has already been made in relatives,
parents may request genetic testing at birth, and whilst this is
not urgent from a clinical point of view, it is possible if the
mutation is known and certainly should be considered by
around the age of 5 years in order to ensure regular monitoring
and early treatment of any proteinuria or hypertension that
may develop: enrolment to early intervention trials also
becomes an option. The use of skin biopsy varies in different
parts of the world and is generally more prominent in America
as it is cheaper than genetic testing. In Israel, a positive skin
biopsy is required to get reimbursement for genetic tests. In
China, skin biopsy is well accepted as it is less invasive and
cheaper. Elsewhere skin biopsies are less likely to be used for
diagnostic purposes as the identification of a specific COL4
mutation is more useful.
Minimum standards for collagen type IV mutation
screening
Sanger sequencing used to be the gold standard, but now
most laboratories use next-generation sequencing to screen the
genes corresponding to the a3, 4 and 5 chains of type IV colla-
gen simultaneously. This is now the gold standard not only for
the speed of the analysis, but also because it ensures the detec-
tion of the digenic forms, i.e. those forms due to mutations in
two different type IV collagen genes. This will detect most point
mutations, but copy number variation analysis is also required;
otherwise, 15% of mutations in the X-linked gene and a smaller
percentage of autosomal mutations may be missed. If next-
generation sequencing is negative, then clinicians may resort to
kidney biopsy (with electron microscopy and immunostaining),
skin biopsy, RNA analysis (obtained from skin or hair root) or
further genetic testing. Renal panels that can be screened by
whole-exome sequencing are being developed, and in some
patients who were initially thought to have AS, mutations in
other genes expressed in the kidney may be identified. There are
clear European and American guidelines for determining the
pathogenicity of variants, and most laboratories participate in
external quality assessment schemes such as the European
Molecular Quality Network. The value of submitting mutations
to databases, together with relevant clinical information, is
undisputed, but it is challenging in practice because of the
resources required to do this. Clinicians (and patients) are
strongly advised to ensure that the testing services they use are
comprehensive and undertaken in accredited labs that meet rel-
evant ISO standards, offering in-house validation of potentially
pathogenic variants that are identified.
Mutations in other genes can also affect the phenotype of
patients who have at least one mutation in a type IV collagen
gene. These include MYH9, CFHR5 and NPHS2, among others
[22]. A novel COL4A1 frameshift mutation was demonstrated
to cause kidney disease without extra renal involvement in a
large Turkish Cypriot family (see Figure 2). Several groups have
now published examples of digenic inheritance in AS, and as
gene panels are more widely used, this list will expand.
Providing a map of genetic mutation screening services
There are a number of useful online resources, including
Gene Tests and the UK GTN website. Orphanet lists some labs,
but is not completely up to date. The main reason that not all
patients are offered genetic testing is primarily due to the cost of
these tests, although if they enable more invasive procedures
such as renal biopsy to be avoided, the net difference may be
less significant. Providing access to genetic testing in developing
countries continues to be a challenge. The tests are expensive,
and unfortunately countries where genetic testing is not avail-
able/affordable are likely to continue to see higher rates of renal
biopsy and skin biopsy. Genetic tests have advantages over
other forms of testing as they make the diagnosis of AS with
U n m e t n e e d s i n A l p o r t s y n d r o m e 919
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|certainty, even in females, who only have haematuria; they also
clearly identify the mode of inheritance which is important for
counselling and may help predict the clinical course.
Easier (and earlier) diagnosis of Alport syndrome in
everyday clinical practice: possible role of a new
classification system
A major requirement for the timely treatment of AS is to
make early diagnosis (of this rather complex type IV collagen
disease with various inheritance paths) easier in everyday clini-
cal practice. Heterozygous individuals at risk of renal failure are
often underdiagnosed. The value of a new, less complex and
broader classification system for all patients who have a COL4
mutation (including those previously labelled as ‘familial benign
haematuria’) was discussed. There are concerns about causing
distress for the parents of a child with isolated haematuria, but
labelling all patients with a COL4 mutation as having AS may
help to ensure that all patients at risk of developing significant
renal disease are offered proper lifelong surveillance and treat-
ment. There is complete agreement as to the need for at least
annual monitoring of blood pressure and screening for protei-
nuria for all mutation carriers. The discussion about a new clas-
sification system for AS continues.
Prenatal diagnosis and pre-implantation genetic
diagnosis
Couples who know that they are at significant risk of having
a child affected with AS may express an interest in prenatal or
pre-implantation genetic diagnosis. This is becoming widely
available in countries where the law permits these reproductive
options, although demand varies. These tests should only be
discussed and offered in the context of genetic counselling if
there is complete confidence at a clinical and genetic level of the
diagnosis including the distinction between monogenic and
digenic forms.
UNMET NEEDS IN CLINICAL CARE: REPORT
OF THE CLINICAL CARE AND REGISTRIES
BREAKOUT GROUP
A diverse group of paediatric and adult nephrologists, clinical
researchers and patient advocacy group representatives con-
vened in breakout sessions over 2 days to discuss priorities for
research into the clinical aspects of care for patients with AS.
The current treatment of chronic kidney disease (CKD) in
children and adults with AS was reviewed. There are currently
no approved therapies specifically designed for AS-related kid-
ney disease. The group members agreed that the current clinical
practice recommendations for treatment with ACE inhibitors
(and angiotensin receptor antagonist as second line) for protei-
nuric individuals in low-risk categories and microalbuminuric
individuals in high-risk categories remain consistent with cur-
rent evidence [20]. The ongoing EARLY PRO-TECT Alport
trial is a double-blind, randomized, placebo-controlled trial of
paediatric patients with isolated haematuria or microalbuminu-
ria comparing disease progression over 3–5.5 years in subjects
treated with ramipril versus placebo [16]. The results of this trial
may influence treatment recommendations for children with
early-stage AS in the near future. Whilst there are retrospective
data from the European Alport Registry to suggest that ACE
inhibitor therapy delays renal failure and improves lifespan,
there was agreement that this analysis should be replicated in
other registries around the world including large numbers of
patients to ensure that it is a consistent finding [18, 19]. Using
additional drugs to lower urinary protein excretion, beyond that
achieved by full-dose ACE inhibition, is not of proven benefit
and may convey additional risk. Further studies in AS and other
proteinuric renal diseases are required before additional drugs
can be recommended. Participants agreed that care of CKD in
children and adults with AS should follow established KDIGO
guidelines [23]. Currently, there is no evidence suggesting that
individuals with AS should have different blood pressure, anae-
mia, cholesterol, parathyroid hormone, etc., targets than the
general CKD population.
The group identified that a major understudied problem in
AS is the hearing loss that occurs in a majority of affected indi-
viduals. Hearing is normal at birth followed by the development
of high-frequency sensorineural hearing loss in 50% of affected
males with X-linked Alport syndrome by the age of 15 years
and 90% by the age of 40 years [24]. Adults with hearing loss
are less likely to complete higher education and may be more
likely to experience depression and career dissatisfaction [25,
26]. Children and adolescents with hearing loss may be further
impacted by teasing and poor interaction with peers [27].
Children and adults with hearing loss and AS are at risk for
lower quality of life measures; however, this has not been eval-
uated in AS patients specifically and may be exacerbated by
their concomitant CKD. Approaches to identify and treat the
psychosocial aspects of hearing loss in this population are
needed.
Strategies to preserve hearing in patients with AS are also
needed. There is some information available about the distribu-
tion of type IV collagen chains in the inner ear in animal models
of AS as well as in humans [28–31]. The structural changes
observed in human Alport cochleae may be associated with
defective attuning of basilar membrane motion and hair cell
stimulation, resulting in reduced acuity of hearing, although the
definitive mechanism for the development of hearing loss is
unclear. Studies of hearing and the effect of therapy on hearing
loss in animal models of AS should be performed. Future clini-
cal trials should include changes in hearing as an outcome
measure if there is any biologically plausible evidence that a new
treatment could modify the hearing loss. In addition, the Alport
community needs to encourage interest and research in AS-
related hearing loss in the otolaryngology and audiology com-
munities via targeted grant opportunities and educational
seminars.
AS is a disease of families, often with multiple affected fam-
ily members. Research into the psychological aspects of every
stage of the disease course is needed, including support at
diagnosis and transition from paediatric to adult providers.
Research is also needed on how to support individuals and
families through stages of hearing loss, CKD, dialysis, trans-
plantation and family planning. Participants agreed that psy-
chosocial support is generally lacking for all children and
920 O. Gross et al.
FIGURE 1: Extract of some of the most important clinical topics discussed at the workshop. Some of the most relevant clinical aspects and
unmet needs were addressed by Clifford Kashtan (clinician’s view) and Sharon Lagas (patient’s view): (i) the value of a new, easier classiﬁcation
of the AS to enable earlier diagnosis and treatment; (ii) the role of biomarkers, international registries and open access to data; (iii) possible
risks (and pricing) of new therapies; (iv) combined effort of researchers, clinicians, patients and the pharmaceutical/biotech industry to ﬁnd
better therapies; and (v) the role of patient organizations. XLAS, X-linked Alport syndrome; ADAS, autosomal dominant Alport syndrome;
TBMN, thin basement membrane nephropathy; ARAS, autosomal recessive Alport syndrome.
FIGURE 2: Poster prizes and young investigator awards of the 2015 International Workshop on Alport Syndrome.
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adults with CKD and that this should be an area of research
focus in the nephrology community. Quality of life measures
should be included in any clinical trials for AS. As AS is a rare
disease, diagnosis-specific resources are most likely to be use-
ful when provided remotely via the internet, ideally translated
into several languages. Several Alport patient advocacy groups
have developed their own methods for patient and family sup-
port. The Alport Syndrome Foundation (USA) offers both
public and private Facebook pages offering advice and fellow-
ship. The Italian Alport association has started a project on
‘recognize Alport syndrome’ on its webpage and distributed a
number of informative brochures in key Italian centres.
Alport UK have launched a study with University of Oxford to
document personal experiences of living with the AS. The vid-
eos and audio material will be featured on the award-winning
website healthtalk.org later in 2016. The AS has a broad geo-
graphic distribution around the world without concentration
in any one geographic or ethnic region. Strategies to support
and promote the standard of care for AS patients in develop-
ing countries are needed. In developing countries, access to
genetic testing and renal biopsy may not be widely available;
however, urine dipstick and ACE inhibitors are relatively inex-
pensive. The International Paediatric Nephrology Association
has sponsored an AS symposium at each of their last several
triennial meetings to increase awareness of AS and treatment
recommendations for clinicians from developing countries.
We would support initiatives through the International
Society of Nephrology to do the same for adult nephrologists.
People with AS often do well following renal transplantation,
with graft and patient survival that is better than the general
end-stage renal disease population; however, they are at risk of
anti-GBM disease post-transplant due to formation of autoanti-
bodies [32, 33]. The incidence appears to be lower than previ-
ously reported, with only 0.4% of patients affected in a recent
retrospective review [34]. Evidence to guide recommendations
for monitoring and treatment of anti-GBM disease is not avail-
able, and this topic deserves further study.
The group considered an international clinical registry to be
an important milestone in developing clinical research in AS
further. A working group that will concentrate on developing
the International Alport Registry was formulated. Such a regis-
try could potentially provide data on the epidemiology and nat-
ural course of AS. Furthermore, it could be used to recruit
patients into clinical trials, and its data could support small clin-
ical trials in a generalized evidence synthesis approach. Smaller
Phase I and IIa/proof of concept (PoC) trials of new investiga-
tive compounds will also rely on validated pharmacodynamic
and clinical efficacy markers. Target-specific pharmacodynamic
markers enable faster selection of effective doses in fewer
cohorts of healthy volunteers in Phase I. Sensitive, specific and
FIGURE 3: Extract of urgent unmet needs validated in panel discussions. Some of the most relevant unmet needs were: (i) the need for a
multi-target, ﬂexible, patient-speciﬁc individual approach for lifelong therapy of AS to minimize the progress of disease; (ii) the need for a less
complicated, straight forward diagnosis; (iii) the need to scientiﬁcally evaluate the outcome of treating young patients on a broad international
basis; (iv) chances to spread the standard of care to developing countries; and (v) the urgent need for new therapies, as industry will make a dif-
ference in the awareness of AS as a treatable disease that requires early diagnosis.
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|ideally non-invasive efficacy markers enable smaller, shorter
Phase IIa PoC trials in rare diseases such as AS.
SUMMARY AND NEXT STEPS
The 2015 International Workshop on Alport Syndrome contin-
ued the successful concept of the workshop in January 2014 [1].
This meeting was organized through the concerted efforts of
patient advocacy groups from four continents. After a very
warm welcome by the organizers, the Dean of the University
Medical Center Goettingen and the German patient organiza-
tion, all delegates expressed their specific interests in the clinical,
genetic and basic science aspects of AS. Importantly, the work-
shop concentrated on the most essential unmet needs in AS, as
addressed by Clifford Kashtan (clinician’s view) and Sharon
Lagas (patient’s view) (Figure 1). A separate publication will
address and discuss the requirement to develop a better under-
standing of the impact of AS on women and girls and relevant
treatment.
More than 30 posters were presented and hotly debated in
panel sessions, thereby contributing significantly to the conclu-
sions of the breakout groups. Eight poster awards and four
young investigator awards were handed over to the best pre-
senters (Figure 2).
A ‘lock-in’ environment provided an internationally diverse
group of physicians, geneticists and scientists from academia
and the pharmaceutical/biotech industry, many of whom were
not specifically AS experts, with opportunities for intense,
open-minded discussions that led to major conclusions. Urgent
unmet needs were addressed (Figure 3) and validated in panel
discussions. The next steps to follow in early 2016 are (i) further
discussion on whether changes to the nomenclature for AS
might assist in earlier diagnosis and (ii) large-scale international
funding applications for a multi-target approach from the basic
and clinical research consortium to investigate diverse aspects
of AS.
Building upon accomplishments from 2014, the 2015
International Workshop on Alport Syndrome further consoli-
dated interactions among the various stakeholder groups and
addressed upcoming steps to move forward in the shared mis-
sion to find a long-term multi-target therapy for AS resulting in
a lifelong delay of renal failure or even a cure.
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ABSTRACT
Severe adverse systemic drug events occur commonly as a result
of treatment of cancer patients. Nephrotoxicity of chemothera-
peutic agents remains a signiﬁcant complication limiting the
efﬁcacy of the treatment. A variety of renal disease and electro-
lyte disorders can result from the drugs that are used to treat
malignant disease. The kidneys are a major elimination pathway
for many antineoplastic drugs and their metabolites. Tumour
lysis syndrome, an emergency in haematooncology, occurs
most often after the initiation of cytotoxic therapy in patients
with high-grade lymphomas and acute lymphoblastic leukae-
mia. Chemotherapeutic agents can affect the glomerulus,
tubules, interstitium and renal microvasculature, with clinical
manifestations that range from asymptomatic elevation of
serum creatinine to acute renal failure requiring dialysis. Some
factors such as intravascular volume depletion, as well as con-
comitant use of other drugs or radiographic ionic contrast
media, can potentiate or contribute to the nephrotoxicity.
Cytotoxic agents can cause nephrotoxicity by a variety of mech-
anisms. The most nephrotoxic chemotherapeutic drug is cispla-
tin, which is often associated with acute kidney injury. Many
other drugs such as alkylating agents, antimetabolites, vascular
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